CD274 and melanoma: Although single use of antibodies against PD-L1 such as durvalumab, avelumab, and atezolizumab has been approved for the use in patients other than melanoma, yet investigations of PD-L1 antibodies in combination with targeted therapy or/and chemotherapy are still underway in the treatment of melanoma.